The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR

Hepatology : Official Journal of the American Association for the Study of Liver Diseases
Junko SugataniT Sueyoshi

Abstract

The UDP-glucuronosyltransferase, UGT1A1, is the critical enzyme responsible for detoxification of the potentially neurotoxic bilirubin by conjugating it with glucuronic acid. For decades, phenobarbital (PB) treatment for hyperbilirubinemia has been known to increase expression of the UGT1A1 gene in liver. We have now delineated the PB response activity to a 290-bp distal enhancer sequence (-3483/-3194) of the UGT1A1 gene. The enhancer contains 3 putative nuclear receptor motifs, and it was activated by the nuclear orphan receptor, human constitutive active receptor (hCAR), in cotransfected HepG2 cells. Bacterially expressed hCAR, acting as a heterodimer with in vitro-translated retinoid X receptor (RXRalpha), only bound to 1 of the 3 NR motifs, named gtNR1 in a gel-shift assay. Consistently, mutations of the gtNR1 site significantly decreased the activation by hCAR of the 290-bp DNA in transfection assays. Moreover, the 290-bp DNA was effectively activated in mouse primary hepatocytes in response to PB, offering an excellent clinical test for the examination of the responsiveness of the UGT1A1 to PB in the human population, particularly individuals with hyperbilirubinemia.

Citations

Apr 19, 2005·Archives of Pharmacal Research·Changjiang XuAh-Ng Tony Kong
Jun 18, 2010·Naunyn-Schmiedeberg's Archives of Pharmacology·Ortrud K Steinlein
Mar 19, 2013·The International Journal of Biochemistry & Cell Biology·Andrew RowlandPeter I Mackenzie
Oct 22, 2003·Molecular Genetics and Metabolism·Rajesh S SavkurThomas P Burris
Dec 5, 2002·Archives of Biochemistry and Biophysics·Yukio YamamotoMasahiko Negishi
Jun 5, 2002·Journal of Hepatology·Saul J Karpen
May 22, 2003·Free Radical Biology & Medicine·Vincent TongFrank S Abbott
Nov 30, 2005·The Pharmacogenomics Journal·M L MaitlandA Di Rienzo
Jun 12, 2003·Nucleic Acids Research·Scott S AuerbachCurtis J Omiecinski
Mar 25, 2008·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jennifer M Phillips, Jay I Goodman
Jan 30, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Tomoya YamadaHideo Kaneko
Feb 24, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jennifer M Phillips, Jay I Goodman
Mar 10, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jennifer M PhillipsJay I Goodman
Jun 2, 2009·Toxicological Sciences : an Official Journal of the Society of Toxicology·Jennifer M PhillipsJay I Goodman
Nov 16, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yu-Kun Jennifer ZhangCurtis D Klaassen
Jun 12, 2013·Journal of Tropical Pediatrics·Kannan VenkatnarayanAshok K Deorari
Jan 21, 2006·Pharmacogenetics and Genomics·Jacqueline RamírezStephen C Strom
Feb 4, 2006·Journal of Pediatric Gastroenterology and Nutrition·Yoshihiro MaruoYoshihiro Takeuchi
Mar 30, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kosuke SaitoMasahiko Negishi
Jan 18, 2006·Annual Review of Medicine·Michel EichelbaumWilliam E Evans
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·T Sueyoshi, M Negishi
Jul 5, 2007·Annual Review of Pharmacology and Toxicology·Jean-Marc PascussiPatrick Maurel
Jun 10, 2010·BMC Gastroenterology·Katsuyuki MatsuiYoshihiro Takeuchi
Feb 17, 2006·Annals of Clinical Microbiology and Antimicrobials·Jiezhong Chen, Kenneth Raymond

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.